Phase 3 Readout

CLRB: Phase 3 Topline: An Open-Label, Multicenter, Randomized, Phase 3 Trial of Iopofosine I 131 Versus Rituximab-Cyclophos

Name: Phase 3 Topline: An Open-Label, Multicenter, Randomized, Phase 3 Trial of Iopofosine I 131 Versus Rituximab-Cyclophos
Start: 2035-01-01
End: 2035-01-01

January 1, 2035 · iopofosine. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: January 1, 2035
Company: Cellectar Biosciences, Inc. (CLRB)
Drug: iopofosine

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: An Open-Label, Multicenter, Randomized, Phase 3 Trial of Iopofosine I 131 Versus Rituximab-Cyclophos

January 1, 2035

CLRB overview →

Company: Cellectar Biosciences, Inc. (CLRB)
Drug: iopofosine
Indication: Waldenstrom Macroglobulinemia; Waldenstrom's Macroglobulinemia Recurrent; Waldenstrom Macroglobulinaemia